Nuvilex Contracts With Inno Biologics, an FDA-Compliant Provider, for Initial Generation of Cloned Cells for Future Phase 3 Clinical Trials
SILVER SPRING, Md., Sept. 17, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc.
(OTCQB:NVLX) ("Company"), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today it has contracted Inno Biologics Sdn. Bhd. to generate cell clones that are the basis of the Company's future Phase 3 cancer clinical trials.